Advanced Renal Cell Carcinoma

Post Hoc Analysis Confirms DFS Benefit of Adjuvant Pembrolizumab in Patients With ccRCC
Results of the phase 3 KEYNOTE-564 study demonstrated the efficacy of adjuvant pembrolizumab for patients with clear cell renal cell carcinoma (ccRCC) and increased risk of recurrence after nephrectomy by prolonging disease-free survival (DFS) compared with placebo. At the 24th Annual Meeting of the Society of Urologic Oncology, Dr. Tian Zhang, of UT Southwestern Medical Center, presented the results of a post hoc exploratory analysis on DFS in patient subgroups from the trial, based on the UCLA Integrated Staging System (UISS) risk groups and disease stage. ...
Advertisement

Latest News

Advertisement

Knowledge Hub Spotlights

Curated clinical content based on conditions, therapies, and technologies

Renal Cell Carcinoma
Renal Cell Carcinoma

Conference Coverage

Advertisement
Advertisement
Trending